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Abstract 
Background: In the past decade, national malaria control efforts in Papua New Guinea (PNG) have received renewed 
support, facilitating nationwide distribution of free long‑lasting insecticidal nets (LLINs), as well as improvements in 
access to parasite‑confirmed diagnosis and effective artemisinin‑combination therapy in 2011–2012.
Methods: To study the effects of these intensified control efforts on the epidemiology and transmission of Plasmo-
dium falciparum and Plasmodium vivax infections and investigate risk factors at the individual and household level, 
two cross‑sectional surveys were conducted in the East Sepik Province of PNG; one in 2005, before the scale‑up of 
national campaigns and one in late 2012‑early 2013, after 2 rounds of LLIN distribution (2008 and 2011–2012). Differ‑
ences between studies were investigated using Chi square (χ2), Fischer’s exact tests and Student’s t‑test. Multivariable 
logistic regression models were built to investigate factors associated with infection at the individual and household 
level.
Results: The prevalence of P. falciparum and P. vivax in surveyed communities decreased from 55% (2005) to 9% 
(2013) and 36% to 6%, respectively. The mean multiplicity of infection (MOI) decreased from 1.8 to 1.6 for P. falciparum 
(p = 0.08) and from 2.2 to 1.4 for P. vivax (p < 0.001). Alongside these reductions, a shift towards a more uniform distri‑
bution of infections and illness across age groups was observed but there was greater heterogeneity across the study 
area and within the study villages. Microscopy positive infections and clinical cases in the household were associated 
with high rate infection households (> 50% of household members with Plasmodium infection).
Conclusion: After the scale‑up of malaria control interventions in PNG between 2008 and 2012, there was a substan‑
tial reduction in P. falciparum and P. vivax infection rates in the studies villages in East Sepik Province. Understanding 
the extent of local heterogeneity in malaria transmission and the driving factors is critical to identify and implement 
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Background
Papua New Guinea (PNG) has the highest transmis-
sion of malaria in the Western Pacific Region, where 
it accounted for 80% of the reported confirmed cases 
in 2018 [1]. The majority of the population in malaria-
endemic areas have some degree of natural immunity 
and, therefore, the prevalence of malaria infection and 
incidence of morbidity are highest in young children and 
pregnant women. In the coastal and lowland inland areas 
along the north coast perennial high intensity malaria 
transmission is present [2–8].
East Sepik Province (ESP) has historically been an area 
of PNG with a high malaria burden, with a peak preva-
lence of 70% (by light microscopy (LM)) in children 
5–9 years of age in the early 1990′s [3], whilst more recent 
studies indicate a lower prevalence [5, 9]. The Anophe-
line spp. fauna in PNG is diverse and includes 16 species 
[10]. The principal malaria vectors in PNG are members 
of the Anopheles punctulatus group of mosquitoes, of 
which  An. punctulatus,  Anopheles koliensis,  Anopheles 
farauti, and Anopheles farauti 4 have been incriminated 
as major vectors [10–14]. The different species have dif-
ferent biting cycles: An. farauti tend to bite mostly dur-
ing the early hours of the evening, and in the case of An. 
punctulatus and An. koliensis, peak activity takes place in 
the early hours of the morning [2].
Plasmodium falciparum and Plasmodium vivax are 
the most abundant species in PNG, though Plasmodium 
malariae and Plasmodium ovale are also present, usually 
in combination with the former two species [15]. Plas-
modium vivax was the predominant species prior to the 
introduction of mass spraying and drug administration 
programmes in the 1950’s, which were intended to elimi-
nate malaria [2, 16, 17], These efforts were subsequently 
abandoned in the 1970’s and a resurgence of P. falciparum 
followed, which remains the dominant species today [2, 
17]. However, in the past decade, renewed malaria con-
trol efforts initiated by the PNG National Department of 
Health with support from The Global Fund to fight AIDs, 
TB and malaria have once again significantly reduced 
the burden of malaria in PNG [18–22]. This National 
Malaria Control Programme (NMCP) has focused on 
the nationwide distribution of free LLINs on a 3-yearly 
cycle since 2008, greater availability of prompt diagnosis 
and effective treatment through the introduction of rapid 
diagnostic tests (RDTs) and artemisinin-based combina-
tion therapy (ACT) in 2011–2012 and a behaviour change 
campaign, “Yumi rausim malaria”, focused on improv-
ing understanding of the best options for prevention and 
treatment of malaria [18, 21, 23]. ESP was among the first 
Provinces in PNG where the LLIN distribution campaign 
was implemented, which together with the availability of 
historical data makes it an ideal location to investigate 
the changing epidemiology of malaria in PNG.
While the previously reported reduction in nationwide 
prevalence and incidence of malaria and all-cause mor-
tality rates in young children are significant achievements 
[18, 21–24], important questions related to the nature 
of the epidemiological transition and long-term impact 
of intensified control on parasite-host-vector interac-
tions remain unresolved. Sustained reduction in malaria 
transmission can lead to a decrease in naturally acquired 
immunity and consequently, a shift in the peak burden 
of malaria infection and illness to older age groups and 
change other risk factors. A declining burden of malaria 
illness and high-density parasite infections can also 
mask a substantial community burden of low-density 
but gametocytaemia infections that sustain transmission 
[25–27]. In addition, the possible differential effects of 
these interventions on the various Plasmodium species 
is important to consider in co-endemic regions such as 
PNG, given the distinct biological differences of the two 
main Plasmodium species. While declining prevalence 
and morbidity have been documented on a regional 
level, the effects of decreasing malaria transmission on 
a smaller geographical scale remain to be investigated. 
Heterogeneities in transmission and disease burden have 
been described at various scales in PNG [4, 21, 25] and 
can be a major challenge to further reducing the burden 
of malaria, as hotspots can act as the source of infection 
for other neighbouring areas [28], and especially P. vivax 
can be resilient [25].
To investigate the impact of the renewed malaria con-
trol efforts on the epidemiology of malaria within com-
munities, data from two cross-sectional community 
surveys conducted in the Maprik and Wosera-Gawi dis-
tricts of East Sepik Province, PNG; one in April–May 
2005, before the implementation of national LLIN dis-
tribution campaign and one in October 2012–February 
2013, were directly compared. Risk factors for parasite 
targeted control strategies to ensure the ongoing success of malaria control in PNG and inform the development 
of tools required to achieve elimination. In household‑based interventions, diagnostics with a sensitivity similar to 
(expert) microscopy could be used to identify and target high rate households.
Keywords: Malaria, Plasmodium falciparum, Plasmodium vivax, Epidemiology, Malaria control, Spatial heterogeneity, 
LLINs
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prevalence, and spatial heterogeneity were investigated 
in addition to gametocytaemia and complexity/multi-
plicity of infection. Understanding the key factors related 
to heterogeneity and residual malaria transmission in 
PNG is critical to support the desired transition from 
nation-wide malaria control to sub-national elimination 
strategies.
Methods
Study design
Two cross-sectional community surveys were con-
ducted in the Maprik and Wosera-Gawi districts in the 
East Sepik Province of PNG; one in April–May 2005 
[9], before the implementation of national LLIN distri-
bution campaign and one in October 2012–February 
2013. The 1st round of LLIN distribution in ESP took 
place in 2008, followed by a second round in 2011–2012. 
LLINs in the study area in ESP were distributed at most 
12 months prior to the 2012/13 survey: September 2011 
(Brukham, Ulupu and Ilahita catchement areas) and 
October 2012 (Wombisa and Burui catchement areas). 
Introduction of a test-and-treat approach and a switch 
to artemether–lumefantrine (AL) as first-line treatment 
and formal adoption of 14  days 0.25  mg/kg primaquine 
for vivax-confirmed malaria occurred at the end of 2011/
beginning of 2012. The Maprik and Wosera-Gawi dis-
tricts, consist of an area of over 160 km2 with low hills, 
plains and riverine plains with a wet tropical climate [3, 
9]. The natural vegetation is lowland hill forest that has 
mostly been replaced by re-growth following cultivation 
and wide grasslands on the plains near the Sepik River. 
The people in this area live in villages of hundred to sev-
eral hundred individuals and the villages are sometimes 
divided in geographically distinct hamlets. The majority 
of the people live from subsistence farming. There are 
several government health centres, church health centres 
and smaller aid posts in the area and the referral hospital 
is in Maprik.
All eligible and willing residents of households in the 
local communities in the study area were invited to par-
ticipate and following written informed consent, demo-
graphic information (age, gender, familial relationship, 
bed net use), history of febrile illness, household or vil-
lage location by GPS receiver and blood samples were 
collected. The design of both studies was similar, and 
details of the 2005 study have been previously described 
[9]. All details of the recent cross-sectional are described 
below. In the 2005 study questions related to bed nets 
were not directed to insecticide treated nets (ITNs) or 
LLINs in particular, and are likely to be untreated nets. 
In 2012–2013, after the start of the large-scale LLIN 
campaigns, questions were asked specifically about 
LLINs and not ITNs or untreated nets. Therefore, when 
variables are reported where the 2005 study is included, 
the term bed nets will be used, while in the 2012–2013 
study the term LLINs can be applied.
Capillary blood (250–300  μL) was collected into 
K + EDTA microtainers, thick/thin films were prepared 
and haemoglobin levels were measured (Hemocue). The 
collected blood was centrifuged, the plasma removed and 
stored at − 80 °C, and the red cell pellet stored at -20 °C 
until DNA extraction. If febrile illness was reported, 
a rapid malaria diagnostic test (Carestart Pf/Pan) was 
performed and those positive by RDT treated with 
artemether-lumefantrine (Coartem). For RNA preserva-
tion, 50 μL of whole blood was immediately transferred 
to a tube containing 250μL of RNAProtect (Qiagen) 
and stored at -80  °C within 8 h of collection until RNA 
extraction.
Plasmodium spp. detection
Giemsa-stained thick and thin films from the 2005 survey 
were examined by LM (minimum of 200-high powered 
fields) by two independent experienced microscopists, 
with discrepancies adjudicated by a third independent 
microscopist, as previously described [9]. All slides col-
lected during the 2012/13 study, were similarly exam-
ined once by experienced microscopists. Slides from LM 
and/or PCR positive individuals and a random selection 
of negative slides were re-examined by an independent 
microscopist with discrepancies adjudicated by a third 
WHO-certified Level 1 or 2 microscopist. Parasite densi-
ties were calculated from the number of parasites per 200 
or 500 white blood cells (WBCs) (depending on parasi-
taemia) and an assumed total peripheral WBC count of 
8000/μL [29], with the final density taken as the geomet-
ric mean of the two values.
The presence of parasite DNA in all blood samples was 
investigated by molecular methods (MM, i.e. qPCR or 
LDR-FMA). In 2005 DNA was extracted from red blood 
cell pellets using QIAmp 96 DNA Blood kits (Qiagen) 
and a post-PCR, ligase detection reaction/microsphere 
assay (LDR-FMA) was used to determine the presence of 
P. falciparum, P. vivax, P. malariae and P. ovale [9, 30]. In 
the 2012/13 survey, DNA was extracted from the equiv-
alent of 200 μL whole blood using the Favorgen 96-well 
Genomic DNA Extraction Kit (Favorgen) following the 
manufacturer’s instructions and eluted in 200  μL. Ini-
tially a generic quantitative PCR (QMAL) that amplifies 
a conserved region of the 18S rRNA gene was run on all 
samples [31]. Species-specific quantitative PCRs (qPCR) 
were then performed on all positive samples as described 
[32]. The qPCR was previously directly compared to 
the LDR-FMA and assays are approximately equivalent 
in sensitivity and specificity [32]. Copy numbers were 
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quantified based on serial dilutions of plasmid controls 
run in parallel.
Gametocyte detection
The number of observed P. falciparum (2005 and 
2012/13) and/or P. vivax (2012/13 only) gametocytes 
were recorded separately from asexual stages during 
microscopic examination of all blood slides. Gameto-
cyte detection by qRT-PCR was performed on samples 
from 2012/13: RNA was extracted from all P. falciparum 
and/or P. vivax qPCR-positive samples using the Qiagen 
RNeasy plus 96 kit, according to the manufacturer’s pro-
cedures. A genomic DNA removal by gDNA eliminator 
columns and DNase (Qiagen) step was included in the 
procedure. Absence of gDNA was confirmed by qPCR 
and presence of parasite RNA after extraction was veri-
fied by qRT-PCR with the same primers and probe as the 
QMAL qPCR described above. P. falciparum and P. vivax 
gametocytes were detected by qRT-PCR of the highly 
expressed gametocyte markers pfs25 and pvs25 as previ-
ously described [31]. The limit of detection of the pfs25 
and pvs25 qRT-PCRs in the laboratory set up in PNG, 
were 6 copies/transcript per reaction for both assays.
Genotyping
To genotype P. falciparum and P. vivax LDR-FMA/qPCR 
positive samples, high-resolution Pfmsp2, Pvmsp1f3 
and PvMS2 genotyping was performed as previously 
described [33, 34]. Briefly, for P. falciparum a nested 
multiplex PCR approach was used to amplify 3D7 and/
or FC27 family alleles of Pfmsp2 using family-specific 
primers labelled with a fluorescent dye, or a multiplex 
primary PCR was used to amplify the markers Pvm-
sp1F3 and PvMS2 with fluorescently labelled primers. 
The PCR products were analysed by 1.5% agarose gel 
electrophoresis and the number and size of alleles were 
then determined by capillary electrophoresis using a 
23 ABI 3730XLs platform (Macrogen, Korea) with the 
internal size standard GSLIZ500 and data were subse-
quently analysed using GeneMarker 2.4.0 demo version 
(SoftGenetics). The multiplicity of infection (MOI) for P. 
falciparum was defined as the number of Pfmsp2 alleles 
counted within a sample, and P. vivax MOI was defined 
by the number of Pvmsp1f3 or PvMS2 alleles, whichever 
was higher.
Data analysis
Raw data from the 2005 survey [9] was reanalysed to 
compare prevalence and predictors with data from the 
2012/13 survey. Clinical malaria cases were defined 
as febrile illness (current or previous 48  h) in the pres-
ence of P. vivax or P. falciparum asexual parasites by LM 
(any density). Symptomatic infections were defined as 
febrile illness (current or previous 48 h) in the presence 
of parasites as detected by LM and/or MM. Parasite den-
sities were log transformed and the geometric mean per 
μL whole blood are reported. Four categories were used 
to describe anaemia: non-anaemia, mild, moderate or 
severe, which were defined based on haemoglobin con-
centrations (measured by Hemocue) and stratified by age 
and gender as per the WHO recommendations (Addi-
tional file 1) [35]. On average, there were 3.7 people in a 
household (3.8 in 2005; 3.5 in 2012–2013). A high-infec-
tion rate household was defined on the basis of having 
more than 50% of household members with a Plasmo-
dium infection (determined by molecular method).
Differences between the two studies were investigated 
using Chi square (χ2) and Fischer’s exact tests for cat-
egorical characteristics and Student’s t-test for normally-
distributed continuous variables. Tests were two-tailed 
and the confidence level was set at 95%. Univariable 
analysis of factors associated with P. falciparum or P. 
vivax infection (determined by MM and/or LM) and high 
rate household were conducted using logistic regression. 
Multivariable logistic regression models were built with 
variables with p < 0.15 in univariate analysis and variables 
were selected using likelihood methods for models with 
minimal Akaike information criterion (AIC). Analyses 
were performed using Stata 12. Genetic diversity analyses 
were done using FSTAT software version 2.9.3.2 to define 
allele frequencies, and the expected heterozygosity (He). 
Household, village and health facility location data were 
collected using a handheld GPS receiver (Garmin GPS-
map62sc). Maps were constructed with collected GPS 
coordinates using ARC GIS Pro 10.4
Results
Study characteristics
A total of 2744 participants from 15 villages in five dis-
tinct geographical areas of East Sepik Province partici-
pated in the 2005 cross-sectional survey. Of these 121 
(4.4%) were excluded because of missing demographic 
or LM data, while insufficient finger-prick blood sample 
for LDR-FMA analysis led to exclusion of an additional 
96 (3.5%) individuals. Overall 2527 participants from 659 
households with complete demographic and infection 
status data were available for comparison with 2012/13 
data. A total of 2500 participants in 14 villages from the 
same areas participated in the 2012/13 cross-sectional 
survey. Of these, 14 (0.6%) were excluded from the analy-
sis because of missing LM results. Overall, 2486 partici-
pants from 704 households with complete demographic 
and infection status data were available.
The two studies were very comparable in their design, 
however, they differed in the demographic and clinical 
characteristics of the participants (Table 1 and Additional 
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file 2). Median age in 2005 was 17 years (range 2.5 weeks–
80 years) and 22 in 2012/13 (range 6 months – 68 years). 
There were three villages from the 2005 study that 
weren’t surveyed in 2012/2013, instead two other villages 
from the same areas were included. As expected after 
two rounds of LLIN distribution (2008 and 2011/12), 
significantly more participants reported using LLINs in 
2012/2013 (94.9%) compared to bed nets in 2005 (88.3%) 
(Table 1). The prevalence of clinical episodes of malaria 
(P. falciparum and/or P. vivax) had dropped from 3.6% to 
2.3% (p = 0.007). There was a lower prevalence of anae-
mia in 2012/13, and accordingly, mean haemoglobin lev-
els were significantly higher in 2012/13 (11.1 ± 1.8 g/dL) 
compared to 2005 (10.5 ± 1.7  g/dL; p < 0.001) (Table  1). 
In addition, a higher proportion of individuals reported a 
current or recent febrile illness in 2012/13 (14.4% vs 7.4% 
p < 0.001).
Prevalence of Plasmodium spp. infections in 2005 
compared to 2012/13
The prevalence of malaria infections decreased from 
44.4% to 8.3% by LM and 73.0% to 12.2% by molecu-
lar methods (MM) (Table  2). The species composition 
remained fairly similar, with P. falciparum the predomi-
nant species in both years (75.2% of all infections in 2005 
and 70.0% in 2012/13 by MM, p = 0.052, χ2), followed 
by P. vivax (48.9% of all infections in 2005, and 45.9% 
in 2012/13 by MM, p = 0.335, χ2). The prevalence of 
both species dropped with similar proportions; in other 
words, for both species the prevalence in 2012/2013 was 
roughly 16% of the prevalence in 2005 (Table 2). A lower 
proportion of infections were P. malariae (p < 0.001, χ2) 
in 2012/13 compared to 2005 while the proportion of P. 
ovale by MM remained similar. The majority of mixed 
infections in both years consisted of P. falciparum - P. 
vivax co-infections, followed by P. falciparum with P. 
malariae and/or P. ovale, as determined with MM. The 
proportion of P. falciparum infections that were sub-
microscopic decreased significantly from 2005 (47.2%) to 
2012/13 (37.4%; p = 0.006), but not for P. vivax (60.4% vs 
54.0%; p = 0.139, χ2). The geometric mean density of par-
asites by microscopy was similar in both years. There was 
a significant increase in the proportion of malaria infec-
tions with any species that were symptomatic, increasing 
from 7.0% in 2005 to 25.3% in 2012/13 (p < 0.001, χ2), as 
there was a higher rate of people reporting febrile illness 
in 2012–2013 (Table 1).
The proportion of P. falciparum infected individuals 
with gametocytes detected by LM increased from 10.6% 
in 2005 to 23.7% in 2012/13 (Table  2). The presence of 
P. falciparum and P. vivax gametocytes in the 2012/13 
survey was also investigated with a qRT-PCR detect-
ing gametocyte specific RNA, and the proportion of P. 
falciparum infections with gametocytes (51.4%) by that 
method was significantly higher than with LM (p < 0.001, 
χ2). Plasmodium vivax gametocytes detected by LM 
were not recorded in 2005. In 2012/13, the prevalence of 
P. vivax gametocytes was 0.8% by LM and 0.9% by qRT-
PCR (Table 2).
Comparing risk factors for Plasmodium spp. infections 
and illness
Village of residence was a risk factor for parasite infec-
tion in both surveys (Table 3). In addition, moderate or 
severe anaemia was a strong predictor for P. falciparum 
infection in both surveys, but not for P. vivax (Table 3). 
While males were more likely to be P. falciparum infected 
than women in 2005 (aOR 1.2 [1.01–1.4], p = 0.04), there 
was no difference in 2012–2013. In 2012–2013, current 
or recent fever was a predictor of P. falciparum infection 
(aOR 2.0 [1.3–3.1], p = 0.005). In contrast, participants 
with recent/current febrile illness were more likely to be 
Table 1 Summary of demographic and clinical characteristics of study participants
A more detailed comparison can be found in Additional file 2. Italics p-values are considered statistically significant (p < 0.05)
2005 2013 p-value
n % n %
Number of participants 2527 2486
Gender (female) 1331 52.7 1438 57.8 < 0.001
Age in years (median [range]) 17 [0–80] 22 [0–68] < 0.0001
Reported use of bed nets/LLINs 2231 88.3 2348 94.9 < 0.001
History of recent malaria infection 409 16.3 137 5.5 < 0.001
History of recent malaria treatment 195 8.0 145 5.87 0.003
Anaemia 2131/2486 85.7 1719/2382 72.2 < 0.001
Current or recent reported febrile illness 186 7.4 356 14.4 < 0.001
Clinical malaria (due to P. falciparum and/or P. vivax) 92 3.6 58 2.3 0.007
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P. vivax infected in 2005, but not in 2012/13 (Table  3), 
and recent anti-malarial treatment was associated with 
reduced risk of P. vivax in 2005. Infection with the other 
species was a predictor for both P. falciparum and P. 
vivax in 2012–2013 (Table 3).
Although there was a considerable reduction in the 
overall prevalence of malaria between 2005 and 2012/13, 
there was no obvious shift in the age of peak prevalence 
of P. falciparum and P. vivax infections (Fig. 1, Table 3). 
However, a more uniform distribution of infections 
across all age groups was observed in 2012/13 compared 
to 2005, with age no longer a significant predictor of P. 
falciparum infection in 2012/13 (Table  3). Plasmodium 
falciparum infections were most frequent in older chil-
dren, especially in 2005 (12–20  years by MM in 2005 
and 6–20 years by MM in 2012–2013) (Fig. 1). Plasmo-
dium vivax prevalence was highest in younger children 
(3–12  years by MM) compared to P. falciparum (Fig.  1 
and Table 3). Compared to 2005, an increase in the pro-
portion of symptomatic infections was seen in most age 
groups in 2012–2013 (Fig. 1), and age was not a signifi-
cant predictor of symptomatic infections in 2012–2013 
(logistic regression, p > 0.05). The increase in proportion 
of symptomatic infections in 2012/13 is especially large 
in children and adults above 12 years; fivefold in the case 
of P. falciparum and 9 to 18-fold in the case of P. vivax 
infections. None of the P. falciparum infections observed 
in 2012/13 between the ages of 0–3 years were accompa-
nied with fever (Fig. 1).
The decrease in the prevalence of P. falciparum and P. 
vivax was much greater in some villages than in others, 
indicative of heterogeneous transmission (Fig. 2). Of the 
12 villages sampled in both years, there were 6 villages 
where the malaria prevalence by MM in 2012/13 had 
declined by more than 90% compared to 2005, 5 where 
the prevalence had reduced by 73–88% and one (Sunuhu) 
where the prevalence in 2012/13 had decreased by only 
28%. These effects were quite similar for both P. falcipa-
rum and P. vivax, while in 1 village in 2012/13 no P. vivax 
infections were detected at all.
Parasite genetic complexity in 2005 compared to 2012/13
The majority of P. falciparum infections detected by LDR-
FMA in 2005 and qPCR in 2012/13 were successfully 
Table 2 Prevalence of Plasmodium spp. infections of study participants
Italics p-values are considered statistically significant (p < 0.05)
2005 (n = 2527) 2013 (n = 2486) p-value
Parasite detection by light microscopy
 All species 1121/2527 44.4% 206/2486 8.3% < 0.001
 P. falciparum 756/2527 29.9% 139/2486 5.6% < 0.001
  Asexual parasites 730/2527 28.9% 128/2486 5.2% < 0.001
  Gametocytes 80/2527 3.2% 33/2486 1.3% < 0.001
  Geometric mean density (SD) 464.2 (6.8) 487.3 (9.3) 0.798
 P. vivax 368/2527 14.6% 69/2486 2.8% < 0.001
  Asexual parasites 69/2486 2.8%
  Gametocytes 19/2486 0.8%
  Geometric mean density (SD) 193.2 (4.2) 218.5 (5.6) 0.531
 P. malariae 99/2527 9.0% 6/2486 0.2% < 0.001
 P. ovale 0/2527 0.0% 2/2486 0.1% 0.246
 Mixed any species 100/2527 6.5% 9/2486 0.4% < 0.001
Parasite detection by molecular method
 All species 1844/2527 73.0% 303/2486 12.2% < 0.001
 P. falciparum 1387/2527 54.9% 212/2486 8.5% < 0.001
  Gametocytes NA 94/2486 3.8%
 P. vivax 901/2527 35.7% 139/2486 5.6% < 0.001
  Gametocytes NA 23/2486 0.9%
 P. malariae 338/2527 13.4% 28/2486 1.1% < 0.001
 P. ovale 121/2527 4.8% 29/2486 1.2% < 0.001
 Mixed any species 723/2527 28.6% 93/2486 3.7% < 0.001
  Mixed with P. falciparum 683/2527 27.0% 86/2486 3.5%
  Mixed non‑P. falciparum 40/2527 1.6% 7/2486 0.3%
 Symptomatic infections of any species 132/2527 5.2% 80/2486 3.2% < 0.001
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Table 3 Multivariable predictors of P. falciparum (A) and P. vivax (B) infections
A. Predictors of P. falciparum infections
2005 (N = 2486) 2012–2013 (N = 2370)
% Pf aOR 95% CI p-value % Pf aOR 95% CI p-value
Female 55.5% 1.0 0.040
Male 57.3% 1.2 [1.01–1.4]
Anaemia < 0.001 0.0029
 No 49.3% 1.0 3.8% 1.0
 Mild 51.2% 1.2 [0.95–1.6] 5.0% 1.1 [0.6–2.0]
 Moderate 60.0% 1.8 [1.4–2.3] 12.0% 1.9 [1.1–3.2]
 Severe 71.7% 3.4 [2.0–5.6] 28.1% 3.9 [1.6–9.8]
Age group < 0.001 0.103
 0–3 25.8% 1.0 6.0% 1.0
 > 3–6 44.4% 2.9 [1.8–4.4] 8.7% 3.2 [0.7–15.3]
 > 6–9 59.5% 5.1 [3.3–7.6] 12.0% 4.6 [1.0–22.0]
 > 9–12 70.2% 8.2 [5.2–12.] 10.7% 4.1 [0.9–19.6]
 > 12–20 73.6% 12.9 [8.3–19.] 9.2% 7.1 [1.5–34.5]
 > 20 54.1% 4.7 [3.1–6.8] 6.3% 4.0 [0.9–18.1]
Current or recent reported febrile illness 0.0050
 No 6.8% 1.0
 Yes 14.8% 2.0 [1.3–3.1]
P. vivax infected by qPCR < 0.001
 No 5.6% 1.0
 Yes 48.1% 5.6 [3.4–9.1]
Village < 0.001 < 0.001
 5. Ilahita 3 57.4% 1.0 2.1% 1.0
 6. Ilahita 4 55.0% 1.0 [0.60–1.5] 3.0% 1.4 [0.3‑6.0]
 7. Sunuhu 81.9% 3.8 [2.2–6.2] 51.4% 26.2 [7.8–88.1]
 4. Urita 61.0% 1.1 [0.71–1.8] 5.0% 1.7 [0.4–6.9]
 3. Salata NA 6.1% 2.7 [0.7–9.9]
 2. Waragom 68.6% 1.6 [0.97–2.5] 16.7% 8.0 [2.2–29.4]
 12. Jama 38.8% 0.4 [0.2–0.6] 3.9% 1.8 [0.4–7.8]
 13. Sengo 54.3% 0.8 [0.48–1.2] 7.5% 4.2 [1.2–14.5]
 14. Maiwi 48.0% 0.6 [0.35–0.9] 13.4% 6.6 [1.7–25.8]
 15. Malba 1 49.7% 0.7 [0.47–1.1] 1.3% 0.6 [0.1–2.9]
 16. Malba 2 58.6% 1.2 [0.73–1.8] 3.6% 2.2 [0.6–8.6]
 17. Yenigo 50.3% 0.9 [0.55–1.3] 0.6% 0.4 [0.0–3.7]
 10. Wapindumaka NA 3.8% 2.1 [0.5–8.5]
 11. Wombisa 53.5% 0.8 [0.51–1.3] 1.0% 0.5 [0.08–3.0]
 8. Wapin 49.3% 0.8 [0.47–1.2] NA
 1. Bonohi 56.4% 1.1 [0.68–1.7] NA
 9. Bangeleko 59.5% 1.0 [0.63–1.6] NA
B. Predictors of P. vivax infections
2005 (N = 2441) 2013 (N = 2324)
% aOR 95% CI p % aOR 95% CI p
Recent reported anti‑malarial treatment < 0.001
 No 38.3% 1
 Yes 22.1% 0.4 [0.3–0.6]
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genotyped (63.0% and 77.8%, respectively). Similarly, P. 
vivax infections were successfully genotyped by at least 
one of two markers Pvmsp1f3 and PvMS2 (63.5% in 2005 
and 64.7% 2012/13). The total number of different alleles 
detected by the markers was lower in 2012/13 than in 
2005, but the most common alleles were similar between 
the 2  years (Additional file  3). The mean multiplicity of 
infection (MOI) decreased from 1.8 to 1.6 for P. falcipa-
rum (p = 0.08, Mann–Whitney U test) and from 2.2 to 1.4 
for P. vivax (p < 0.001, Mann–Whitney U test). However, 
the proportion of P. falciparum multiple clone infections 
(MOI > 1) remained constant (45.4% in 2005 vs 42.4% in 
2012/13; p = 0.478, χ2), while the proportion of P. vivax 
multiple clone infections decreased from 58.2% in 2005 
to 31.1% in 2012/13 (p < 0.001, χ2). In addition, 54% of 
P. vivax single clone infections were sub-microscopic in 
2012/13, and MOI was significantly associated with sub-
microscopic P. vivax infections in both years (p < 0.001, 
% indicate proportion infected with P. falciparum or P. vivax detected by LDR-FMA (2005) or qPCR (2013) and/or LM within the designated group
aOR multivariable adjusted odds ratio, CI confidence interval
Italics p-values are considered statistically significant (p < 0.05)
Table 3 (continued)
B. Predictors of P. vivax infections
2005 (N = 2441) 2013 (N = 2324)
% aOR 95% CI p % aOR 95% CI p
Current or recent reported febrile illness 0.006
 No 37.9% 1.0
 Yes 25.6% 0.6 [0.4–0.9]
 Female 34.8% 1.0 0.077
 Male 39.5% 1.2 [0.98–1.4]
Age group < 0.001 0.0030
 0–3 24.3% 1.0 6.5% 1.0
 > 3–6 49.0% 3.0 [1.9–4.7] 7.5% 1.4 [0.3–5.8]
 > 6–9 48.7% 2.8 [1.9–4.3] 10.7% 2.2 [0.5–9.1]
 > 9–12 53.1% 3.4 [2.2–5.3] 11.7% 2.8 [0.7–11.8]
 > 12–20 37.1% 1.7 [1.1–2.6] 5.8% 1.3 [0.3–5.2]
 > 20 29.7% 1.1 [0.8–1.7] 3.8% 0.9 [0.2–3.7]
P. falciparum infected by qPCR < 0.001
 No 3.3% 1.0
 Yes 32.7% 4.9 [3.1–7.8]
Village 0.0012 < 0.001
 5. Ilahita 3 38.6% 1.0 2.1% 1.0
 6. Ilahita 4 37.8% 1.1 [0.7–1.7] 2.4% 1.1 [0.2–5.1]
 7. Sunuhu 40.3% 1.1 [0.7–1.8] 36.0% 11.9 [3.5–40.4]
 4. Urita 46.9% 1.3 [0.8–2.1] 9.0% 4.2 [1.2–14.9]
 3. Salata NA 5.3% 2.4 [0.7–8.6]
 2. Waragom 42.0% 1.1 [0.7–1.7] 8.4% 3.5 [0.9–13.7]
 12. Jama 29.1% 0.6 [0.4–1.0] 3.1% 1.3 [0.3–6.1]
 13. Sengo 26.2% 0.5 [0.3–0.8] 4.4% 1.8 [0.5–6.3]
 14. Maiwi 36.4% 0.8 [0.5–1.3] 2.9% 0.9 [0.1–5.4]
 15. Malba 1 44.9% 1.2 [0.7–1.9] 1.6% 0.7 [0.2–3.4]
 16. Malba 2 42.2% 1.1 [0.7–1.8] 1.7% 0.7 [0.1–3.4]
 17. Yenigo 36.9% 0.9 [0.5–1.4] NA
 10. Wapindumaka NA 0.5% 0.2 [0.02–2.0]
 11. Wombisa 34.9% 0.8 [0.5–1.3] 0.5% 0.2 [0.02–2.3]
 8. Wapin 29.9% 0.6 [0.4–1.1] NA
 1. Bonohi 34.7% 0.8 [0.5–1.3] NA
 9. Bangeleko 33.1% 0.7 [0.4–1.1] NA
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logistic regression). Despite the significant decrease in 
prevalence, the overall genetic diversity (He) was high in 
both years for both species (Table 4). Despite large differ-
ences in prevalence in 2012–2013, MOI and He were very 
similar across catchment areas (Table 4) and villages, and 
diversity seemed lowest in the highest prevalence area.
In both years, the majority of P. falciparum infections 
in individuals over 12 years were single clone infections, 
whereas between the ages of 3 to 12  years more multi-
ple clone infections were found (Fig.  3a). Single clone 
P. vivax infections were similarly distributed between 
all age groups in 2005, however, in 2012/13, there was a 
significantly higher proportion of P. vivax single clone 
infections in ages above 9 years (Fig. 3b). The proportion 
of multiple clone P. falciparum and P. vivax infections are 
quite evenly distributed in the different areas, despite dif-
ferences in prevalence between the villages in both years 
(Figs. 3c, d).
Heterogeneity of infection at the household level
Overall, considerably fewer households were affected 
by malaria infections in 2012/13 than in 2005. In 2005, 
96.5% of all households had 1 or more individuals with 
an infection (detected by LM and/or MM), while in 
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Fig. 1 Age distributions of malaria prevalence. Top 4 panels: P. falciparum or P. vivax prevalence by LDR‑FMA or qPCR, prevalence by light 
microscopy and proportion symptomatic P. falciparum or P. vivax infections. Bottom panels: prevalence of P. malariae and P. ovale. Error bars 
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Page 10 of 18Kattenberg et al. Malar J          (2020) 19:198 
0 2.375 4.75 9.5 Kilometers
Health centres and hospitals
Bonohi Waragom
Salata
Urita
Brukham HC
Sunuhu
Ilahita 4
Ilahita HC
Ilahita 3
Sikamo HC
Yenigo
Malba 2
Malba 1 Ulupu HC
Maprik Hospital
PNG IMR
Kombikum HC
Balif Clinic
Amahup Clinic
Wapin
Wapindumaka Wombisa HC
Wombisa
Bangeleko
Jama
Sengo
Maiwi
Burui HC
Villages 2005 & 2012/13
Villages 2005 only
Villages 2012/13 only
P. falciparum prevalence
P. vivax prevalence  
Roads
0%
20%
40%
60%
80% Proporon of parcipants 
infected in all villages 
0%
20%
40%
60%
80%
0%
20%
40%
60%
80%
0%
20%
40%
60%
80%
0%
20%
40%
60%
80%
0%
20%
40%
60%
80%
0%
20%
40%
60%
80%
0%
20%
40%
60%
80%
0%
20%
40%
60%
80%
0%
20%
40%
60%
80%
0%
20%
40%
60%
80%
0%
20%
40%
60%
80%
0%
20%
40%
60%
80%
0%
20%
40%
60%
80% 0%
20%
40%
60%
80%
0%
20%
40%
60%
80%
0%
20%
40%
60%
80%
0%
20%
40%
60%
80%
Fig. 2 Map of study area with village‑specific malaria prevalence in 2005 and 2013. Red bars indicate P. falciparum prevalence and blue bars P. vivax 
prevalence. Villages with a blue symbol (pentagon) were included in both surveys, villages with a green symbol were included in the 2005 survey 
only and villages with a purple symbol were included in the 2012–2013 survey only
Page 11 of 18Kattenberg et al. Malar J          (2020) 19:198  
2012–2013 only 27.8% of households had an individual 
with a LM and/or MM-detectable infection (χ2 p < 0.001). 
As expected, the proportion of households that were 
infected in 2012–2013 was highest in villages with rela-
tively higher prevalence of infection. In 2005, the major-
ity of households had 2 or more individuals infected 
(81.1% of all infected households), whereas in 2012–2013, 
the majority of infected households had only 1 individual 
infected (61.7% of infected households) (Fig. 1). Although 
self-reported LLIN/bed net ownership or use was not a 
significant predictor of malaria infection or illness at the 
individual level, household-stratified analysis revealed 
that a higher prevalence of malaria in a village (any spe-
cies by LM and/or PCR) was significantly associated with 
lower proportion of self-reported bed net/LLIN use in 
the household in both years (p ≤ 0.004, linear regression 
corrected for mean age).
In 2005, 76.4% of the infected households were high-
infection rate household (more than 50% of individu-
als in the household infected), whereas in 2012–2013, 
this had decreased to 27.6% (p > 0.001) and the propor-
tion of high-infection rate households (of all infected 
households) was associated with prevalence in the vil-
lage in both years (linear regression, p < 0.001). A higher 
proportion of reported bed net use in the household was 
associated with a reduced risk of the household being a 
high rate household in 2005 (Table 4), but not in 2012–
2013 when reported LLIN use was very high (95%, see 
Additional file 2). Predictors of high-infection rate house-
holds in 2012/13 were households with the presence of 
clinical cases, microscopic infections and/or gametocyte 
carriers (Table 5).
Discussion
In the historically high transmission region of ESP in 
PNG, a dramatic change in the burden and epidemiol-
ogy of malaria was observed over the period of time 
coinciding with the scale-up of control via nationwide 
LLIN distributions and strengthening of malaria diagno-
sis and treatment at peripheral health facilities. Overall 
Plasmodium prevalence as detected by LM and/or MMs 
has declined from 74.2% in 2005 to 12.8% in 2012/13, a 
substantially sharper decline than has been observed in 
another study area along the North Coast of Papua New 
Guinea [36]. Alongside the reduction in prevalence and 
complexity of infections, a shift towards a more uniform 
distribution of infections and illness across age groups 
Table 4 Genetic diversity, prevalence and  multiplicity of  infection of  P. falciparum and  P. vivax infections at  the  health 
centre catchment area level
MOI mean multiplicity of infection, He expected heterozygosity. Diversity calculation for P. vivax in Ulupu in 2012–2013 was not calculated due to small sample size
2005 2012/13
Prevalence (%) MOI He Prevalence MOI He
Pfmsp2
 Overall 54.9 1.8 0.94 8.5 1.6 0.91
 Ilahita 63.8 2.2 0.93 21.6 1.6 0.88
 Brukham 60.8 1.9 0.94 8.8 1.4 0.93
 Burui 43.4 1.4 0.95 7.9 1.5 0.94
 Ulupu 52.2 1.7 0.92 1.9 1.5 0.97
Wombisa 53.8 1.7 0.94 2.5 1.6 0.83
Pvmsp1f3
 Overall 35.7 2.1 0.89 5.6 1.4 0.90
 Ilahita 37.2 2.7 0.91 15.0 1.4 0.85
 Brukham 39.8 2.3 0.92 7.2 1.3 0.92
 Burui 28.4 1.6 0.88 3.8 1.3 0.94
 Ulupu 39.9 2.1 0.88 1.2 1
 Wombisa 32.4 1.9 0.88 0.5 N/A
PvMS2
 Overall 35.7 1.8 0.91 5.6 1.3 0.90
 Ilahita 37.2 2.3 0.91 15.0 1.2 0.91
 Brukham 39.8 1.8 0.91 7.2 1.2 0.92
 Burui 28.4 1.7 0.93 3.8 1.4 0.87
 Ulupu 39.9 1.8 0.91 1.2 1.8
 Wombisa 32.4 1.6 0.91 0.5 N/A
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but greater heterogeneity in transmission across the 
study area and within the study villages was observed.
Heterogeneity in malaria prevalence between villages is 
not a new phenomenon [3, 4, 37–39]. In the 2012–2013 
study, transmission in some villages had not declined as 
much as in others, increasing this difference between and 
within villages. In those areas with higher prevalence, 
reported use of LLINs was lower and anaemia and fever 
were more prevalent. While coverage of bed nets was 
already high in this area in 2005 (88.3%), the majority of 
nets at that time were untreated nets, whereas in 2012–
2013 most people should have had access to LLINs, and 
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questions specified LLINs. In the village with the highest 
prevalence, Sunuhu, LLIN use was lowest, which could 
be a major factor contributing to the high level of trans-
mission in that village. The use of insecticide-treated nets 
(ITNs) has been shown in many studies to be effective in 
reducing mortality and morbidity from malaria [40–42]. 
In addition, it is thought that use of ITNs leads to com-
munity-level effects, where the majority of the popula-
tion (even those not using ITNs) are protected when ITN 
coverage in the community is high, due to reduction in 
the number of infected mosquitoes and mosquito sur-
vival [43–46]. This effect has, however, not been well 
quantified and impact of LLINs varies with the coverage 
rate. In addition, the required coverage might be different 
for different areas, depending on local factors such as the 
anopheline density, species composition and both vector 
and human behaviour [47].
Renewed political and financial will to strengthen 
malaria control at the beginning of the millennium, 
resulted in the PNG National Department of Health 
launching a new campaign to quickly achieve high levels 
of LLIN ownership and usage. Nationwide free LLIN dis-
tribution took place between 2004 and 2009 and resulted 
in a significant increase in ownership of bed nets (any 
type 80.1%; LLINs 64.6%) [20]. Despite this increase, 
reported LLIN use remained low (32.5%), and the major-
ity of people not using nets reported not having access to 
(unoccupied) nets [20]. A second round of country-wide 
LLIN distribution was conducted between 2010 and 2014 
to cover the gaps in mosquito net coverage [21]. LLINs in 
the study area in ESP were distributed 12  months prior 
to this 2012/13 survey (September 2011 and October 
2012) and a new round of LLIN distribution occurred in 
2014/2015 (personal communication, NMCP/Rotarians 
Against Malaria). Large-scale LLIN distribution cam-
paigns were performed in ESP earlier than in many other 
provinces with a high malaria burden, and LLIN cover-
age in ESP seems to be higher than on the North Coast 
area in general [21, 36], likely due to a higher density of 
nuisance biters encouraging greater use of LLINs. The 
substantial impact of LLINs on transmission in this area 
might also be due to the fact that transmission in ESP is 
Table 5 Multivariable predictors of  households with  high proportion of  household members with  MM-detectable 
infections (> 50%), adjusted for mean age in the household
CI confidence interval, hh household, LM light microscopy, MM molecular method, Nhh number of households
Italics p-values are considered statistically significant (p < 0.05)
Predictors of households with a high proportion of MM-detectable infections
2005 (Nhh = 659) aOR [95% CI] p-value
Proportion of hh members reporting use of bed net 0.4 [0.2–0.8] 0.012
Moderate or severe anaemia in the hh 1.0 [0.6–1.7] 0.95
Microscopic infections in the hh 5.9 [3.8–9.1] < 0.001
Gametocyte carrier (by LM) in the hh 3.7 [1.4–9.4] 0.007
2012–2013 (Nhh = 430) aOR [95% CI] p-value
Clinical case in the hh 2.6 [1.0–6.9] 0.05
Microscopic infections in the hh 4.8 [1.4–16.4] 0.012
Gametocyte carrier (by LM) in the hh 3.8 [1.4–10.6] 0.011
Ilhaita_4 (reference) 1.0
Sunuhu 34.9 [4.1–299.3] 0.001
Urita 1.7 [0.1–30.1] 0.733
Salata 7.2 [0.8–65.5] 0.078
Waragom 4.3 [0.4–51.2] 0.246
Jama 1.7 [0.1–30.2] 0.725
Sengo 1.8 [0.2–19.5] 0.610
Maiwi 7.7 [0.6–107.8] 0.129
Ilhaita_3 No high rate households
Malba_1 No high rate households
Malba_2 No high rate households
Yenigo No high rate households
Wapindumaka No high rate households
Wombisa No high rate households
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predominantly driven by An. punctulatus, which feeds 
later at night (after midnight/early morning) and equally 
indoors and outdoors, making it highly susceptible to 
LLINs. A recent study reported an increase in preva-
lence of An. punctulatus and a decrease of An. koliensis, 
another late biter, in an adjacent area in East Sepik prov-
ince, as well as a shift to earlier mean biting times of An. 
punctulatus in addition to significantly reduced man-
biting-rates and annual entomological inoculation rates 
after the LLIN campaign [48]. Proximity to vector-breed-
ing sites is related to the risk of malaria and can also be a 
main driver of heterogeneity [49–51], but was not inves-
tigated in the current study.
Cultural factors, socio-economic status and education 
level play an additional role in risk of infection and can 
vary across villages and households, as well as human 
behavioural and genetic factors [9, 21, 28, 52–56]. The 
time and manner of LLIN distribution in these areas can 
play a role in their availability, use and quality/age of the 
LLIN. For example, in some areas the LLINs might have 
been distributed directly to each household, whereas in 
other areas, people will have gone to their local health 
centres to obtain their LLINs. There are also real or per-
ceived differences in the availability of RDTs, effective 
anti-malarials and quality of care received at the health 
centres [19]. In Sunuhu, for example, the population is of 
a different ethnic origin than surrounding villages, more 
closely related to the population in Gwanga local level 
government (LLG) than Ilahita LLG. The Sunuhu popu-
lation have less material wealth, less access to nutritious 
food, and rates of malnutrition and generally poor health 
are more common than in neighbouring villages. They 
may also be less likely to access care at the nearby health 
centre (due to distance, cultural difference, perceived 
benefit) and it is possible their access to LLINs has been 
reduced as a result.
Despite the decrease in prevalence and significant geo-
graphic heterogeneity, the genetic diversity of both P. fal-
ciparum and P. vivax appears to have been maintained at 
relatively high levels. Multiplicity of infection and espe-
cially the proportion of multiple clone infections has 
decreased. The proportion of multiple clone infections 
correlated well with prevalence and might be a suitable 
indicator of hotspot areas and areas of high transmission. 
Further investigation of markers that are not under selec-
tive pressure is required for a more detailed analysis of 
the impact of malaria control on genetic diversity, differ-
entiation and population structure in this area [57, 58].
Although the prevalence of malaria has decreased 
across all age groups and there is no marked shift in the 
peak age of infections (compared to the 2005 survey 
and others [5]), there is a relatively higher proportion 
of symptomatic infections in the 2012/13 survey). This, 
together with a five- to ninefold increase in the propor-
tion of symptomatic infections in adults is an indica-
tion that there might be reduced or delayed acquisition 
of immunity. More detailed investigations on the effect 
of the decreased transmission intensity on the inci-
dence (and complexity) of malaria infections and clinical 
malaria episodes, and age/exposure related acquisition of 
clinical immunity are being conducted in several longitu-
dinal child cohorts in East Sepik and Madang Province.
The impact on the prevalence of P. vivax was similar or 
higher as on P. falciparum, in 10 of 12 villages surveyed 
in both years. Based on the biology of relapsing P. vivax 
infections from hypnozoites and the fact that neither 
LLINs nor ACTs act to prevent these relapsing infections 
it is generally thought that P. vivax burden is more resil-
ient to these tools and that an equivalent impact may not 
be observed in the same timeframe as for P. falciparum. 
In the same area as this study, a series of cohort studies 
showed that while P. vivax clinical episodes declined at 
rates comparable to P. falciparum, force of blood stage 
infections and prevalence took longer to decline [59]. 
The data presented here suggest that 8 years post-scale-
up of LLINs appears to be a sufficient length of time for 
the hypnozoite burden to have been exhausted in most 
villages.
Although the two studies were not conducted at the 
same time of the year (April–May in 2005 vs. Oct-Feb in 
2012–2013), this difference in timing is unlikely to sub-
stantially contribute to the observed decrease in preva-
lence between surveys. The ‘wet’ season is usually from 
October–April, whereas the so-called ‘dry’ season runs 
from May–September, however, in most parts of the 
lowlands of PNG there is perennial malaria transmis-
sion, with limited seasonality [2, 4, 8]. Previous repeated 
cross-sectional surveys in the neighbouring Wosera 
area showed no clear-cut seasonal patterns [3, 5] and a 
detailed paediatric longitudinal cohort showed increased 
transmission during the rainy season [60, 61]. In addition, 
a substantial decline in infection prevalence and clinical 
malaria episodes was also observed in three longitudinal 
child cohort studies conducted in the same area spanning 
a similar time period [59].
A limitation of the study was that the MM used to 
detect infections in the two time-periods was not the 
same. However, a previous study directly comparing 
qPCR and LDR-FMA reported substantial agreement 
between the two methods [32]. While the LDR-FMA 
detected slightly higher numbers of P. falciparum infec-
tions in that study (47% vs 41%) [32], this is not sufficient 
to be responsible for the observed difference in preva-
lence between the two studies, which mirrors the drop 
in prevalence by LM. The decreased prevalence of sub-
microscopic P. falciparum and P. vivax infections in the 
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2012/13 study is potentially influenced by the difference 
between qPCR and LDR-FMA and thus the data from 
this earlier survey will appear to have a slightly higher 
proportion of sub-microscopic infections than when 
qPCR was used. In addition, 2nd reads of microscopy 
slides in 2012–2013 were performed based on qPCR 
results, potentially resulting in a lower proportion of sub-
microscopic infection.
This study was not a formal component of the moni-
toring and evaluation of the national malaria control pro-
gramme, with the primary aim to delve into the impact 
that reduced transmission is having on the epidemiology 
of malaria rather than assess the programme itself. Preva-
lence reported in this study is much higher than provin-
cial averages from the national reports [22, 62], which to 
a large extent can be explained by the higher sensitivity 
of the MM that were used in these studies as compared 
to microscopy and RDTs. Molecular tools are much more 
sensitive at detecting low levels of parasitaemia and are 
therefore crucial to get a detailed insight on the preva-
lence of not only clinical disease, but also asymptomatic 
reservoirs of infection. Microscopic infections in the 
household, as well as gametocyte carriers were associated 
with high rate infection households in both years and in 
2012–2013 many high rate households contained clini-
cal cases, highlighting the utility of clinical and micros-
copy-based surveillance to identify transmission foci that 
could be specifically targeted with interventions aimed 
at reducing not only clinical cases, but the asymptomatic 
reservoir as well. Although the national programme is 
very effective in determining the impact on a national 
level, this study facilitates the investigation at a different 
level of sensitivity, geographical scale and subsequent 
detection of fine-scale heterogeneity in transmission.
Identifying and targeting focal points and hotspots of 
malaria is highly relevant for malaria control, since these 
are likely to be the areas where residual malaria transmis-
sion will persist, and can become an obstacle in efforts 
to eliminate malaria [28, 63, 64]. In addition they can 
play a catalysing role: hotspots fuel transmission within 
transmission foci, and interventions targeted at trans-
mission hotspots therefore have the potential to reduce 
community-wide malaria transmission [28, 64]. Many 
of the high burden villages found in 2012/13 were also 
areas of the highest prevalence in 2005, and it remains 
to be seen if these same areas are still high in prevalence 
in future. If these hot spots are consistently at the same 
location, implementation of control tools to target them 
will be much easier. In other regions in the world, it has 
been observed that hotspots are remarkably stable even 
when transmission intensity declines, although clini-
cal incidence might vary with time [28, 65–67]. In addi-
tion to scaling up conventional vector control tools such 
as LLINs and indoor residual spraying in these hotspot 
areas, other tools could be implemented that might prove 
more useful in these particular areas. Ongoing entomo-
logical studies in East Sepik and Madang provinces may 
advise on the suitability of additional vector control tools. 
Alternatively targeting the parasite via interventions 
to reduce the infectious reservoir in these communi-
ties, such as mass screening and treatment (MSAT) and 
mass drug administration (MDA). Modelling has shown 
that MDA targeting blood and liver stage drugs might 
be more effective in reducing P. falciparum and P. vivax 
prevalence than MSAT [68] and implementation of such 
strategies may be feasible to achieve in these relatively 
small communities.
Conclusions
Although Papua New Guinea’s strengthened malaria 
control programme successfully reduced malaria prev-
alence nationwide between 2005 and 2013, with a 
substantial impact in ESP, areas with high ongoing trans-
mission remain. In this study, LLIN coverage and use, 
socioeconomic factors, vector density/behaviour and 
environmental factors are the likely drivers of this het-
erogeneity and resilience in the face of control. In order 
to further reduce transmission in these areas, additional 
surveillance approaches, novel tools and community 
engagement strategies may need to be layered on top of 
sustained nationwide LLIN coverage and effective case 
management.
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